Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors
J. Zhou, C. Gelot, C. Pantelidou, A. Li, H. Yucel, R. E. Davis, A. Farkkila, B. Kochupurakkal, A. Syed, G. I. Shapiro, J. A. Tainer, B. S. Blagg, R. Ceccaldi, A. D. D'Andrea
The paper identifies Novobiocin as a POLθ inhibitor that selectively kills HR-deficient tumors, including those resistant to PARP inhibitors.
bioRxiv · May 23, 2020Cancer Biology